Public Health and Pharmacy Formulary Advisory Committee Meeting  
July 13, 2018, 8:30am  
Portland State Office Building, 800 NE Oregon St. Portland, OR 97232  
Conference Room 1A

<table>
<thead>
<tr>
<th>Committee Members – all present</th>
<th>OBOP Staff to Committee – all present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evon Anukam, RPh</td>
<td>Marcus Watt, Executive Director</td>
</tr>
<tr>
<td>Kat Chinn, RN MSN</td>
<td>Rachel Melvin, Executive Support Specialist</td>
</tr>
<tr>
<td>Sean Jones, MD</td>
<td>Fiona Karbowicz, Pharmacist Consultant</td>
</tr>
<tr>
<td>Amy Valdez, RPh</td>
<td>Brianne Efremoff, Compliance Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agenda Item</th>
<th>Desired Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>Called the meeting to order @ 8:30AM - Roll call – all Committee members present.</td>
</tr>
<tr>
<td></td>
<td>Introductions of public attendees</td>
</tr>
<tr>
<td></td>
<td>Agenda review and approval</td>
</tr>
<tr>
<td></td>
<td>Motion to approve the agenda was made and unanimously carried (Motion by Helm, seconded by Burns).</td>
</tr>
<tr>
<td></td>
<td>2.16.18 Minutes review and approval</td>
</tr>
<tr>
<td></td>
<td>Motion to approve the 2.16.18 Committee Minutes was made and unanimously carried (Motion by Chinn, second by Anukam).</td>
</tr>
</tbody>
</table>

Committee Business  
Committee Updates:  
- The Committee scheduled time with Board Counsel, Tom Cowan. Attorney Cowan explained his role with Board and discussed objectivity and the environment for this Committee. He talked about the formality of the communication for the Committee and that there are public records and meetings laws in Oregon, which allow public transparency. Systematic approach to your communication and mindful of the public record. Tom and Committee members discussed occasions when recusal may and may not be warranted, as well as the best methods for internal and external communications.  
- The Committee discussed the creation of a new procedure for approval of minutes, in order to not have to wait until the next meeting, at least three months away. The Committee agreed to meet via phone conference approximately 3 weeks after each meeting (perhaps on Friday mornings) solely for the purpose of approving minutes.  
- Rules development update (this will be a standing agenda item)  
  - Pharmacist Consultant Fiona Karbowicz reported that Division 20 is the landing area for the Committee’s work. The Committee’s first rule is in effect now.  
  - As the process develops, the dedicated webpage will be where we house all of the information from this Committee.  
  - The Committee discussed the step-by-step process of how their review and recommendations of concepts move through the review and adoption of codified rules by the Board.  
    - Stakeholders may submit concepts for Committee review → Committee recommendations votes are passed along to the Board → Board codifies rules for
Formulary addition and votes to send to rulemaking → Stakeholders and public may provide written/verbal testimony → Board adopts final rules, incorporating new items to the Formulary

- High priority items to review at this meeting:
  - none

- Review of Submitted Concepts:
  - Topical Pain Cream Concept - submitted 3/18/18
    - This concept contemplates the addition of topical pain creams, general and compounded products, to be added to the Formulary.
    - The Committee discussed concerns related to this concept. Members cited increased (both federal and state) scrutiny on these types of products and of concern was the increased potential for fraud, waste and abuse, particularly when the RPH would be the sole provider (both prescriber and dispenser).
    - Evon asked if we reach out to the sender of the concept after we approve or deny their request. Fiona stated that the Committee’s decision will be responded to the senders.

Motion against recommending Compounded Topical Pain Creams to the Formulary list for the Oregon Board of Pharmacy was made and unanimously carried (Motion by Helm, seconded by Turner)

- Emergency Contraception Concepts - submitted 4/21/18 and 5/5/18
  - Two concepts were received related to the addition of emergency contraception to the Formulary.
  - The Committee discussed the current contraception rules in regards to the product and age restrictions. It was noted that none of the products (such as Plan B or other “me too” products) require ID anymore, some packaging still has mention of age 17, which can still lead to confusion. Committee decisions for recommendation:
    - No age restriction;
    - No mention of gender;
    - No limitations on frequency or quantity.
  - The Committee discussed the potential benefit to patients utilizing a pharmacist for both the OTC and prescription emergency contraception, particularly due to increased “after hours” access, professional consultation, as well as the possibility of insurance coverage.
  - The Committee discussed “stigma” concerns, in light of recent media coverage. It was noted that the Oregon Board of Pharmacy worked to address this in 2005 with the creation of its position statement “Considering Moral and Ethical Objections”. A pharmacy is required to adhere to written policies and procedures that address a pharmacists’ moral, ethical and professional responsibilities, to ensure a patient’s access to care.
  - The Committee discussed whether there was a need to specify an additional mandated education requirement within the recommendation. It was determined that this was not required, but suggested, perhaps with links to additional CE or training made available to pharmacists.
  - The Committee determined that a specific protocol would not be needed, nor is that the responsibility of a regulatory agency. However, it was recommended that the pharmacy association may consider developing “model” policies and procedures and “model” protocols to assist in these efforts.
Motion to recommend Emergency Contraception, not including abortifacients, no additional required education, and following established core elements to the Protocol list for the Oregon Board of Pharmacy adopt by rule was made and unanimously carried (Motion by Burns, second by Jones).

- Uncontrolled Hypertension Concept – submitted 5/8/18
  - This concept contemplates the addition of anti-hypertensive medications to be added to the Formulary.
  - The Committee members discussed the pros and cons of the concept and the many components and logistical issues. Chair Valdez stated that this might be addressed in the future with the Continuation of Therapy rule where Pharmacists could impact this issue in a positive manner.
  - It was noted that pharmacists can play a critical role in the medication management of hypertension patients and assisting with medication regimen adherence. However, these efforts have the most positive impact when the pharmacist is working as member of a patient’s care team. The Committee discussed the value of increased utilization of Collaborative Drug Therapy Management agreements to care for hypertensive patients, as initiating modifying or discontinuing medications cannot be made on a single blood pressure reading. Additionally, safe care can be provided best when a pharmacist has access to the Electronic Health Record.
  - The Committee stated that the scope of this concept was too broad and it would be willing to address future submissions of smaller, more specific scope related to hypertension.

Motion to not recommend Uncontrolled Hypertension Concept submitted on 5/8/18 to the Protocol list for the Oregon Board of Pharmacy was made and unanimously carried (Motion by Turner, seconded by Chinn).

- Webpage link:

  [https://www.oregon.gov/pharmacy/Pages/PharmacyFormularyAdvisoryCommittee.aspx](https://www.oregon.gov/pharmacy/Pages/PharmacyFormularyAdvisoryCommittee.aspx)

Good of the Order

- Wrap up and next steps – The Committee summarized what concepts they recommended and did not recommend.
- Next meeting
  - October 26, 2018
- 2019 tentative meeting schedule
  - January 11, 2019 – room 1D (Note: need to vote for a new Committee Chair)
  - April 12, 2019 or May 3, 2019 – room 1D
  - July 12, 2019 – room TBD
  - October 11 or 25, 2019 – room TBD

Amy Valdez adjourned the meeting at 11:30AM.